Epithelioid Hemangioendothelioma — Trials

Epithelioid Hemangioendothelioma — Trials · CancerIndex

Clinical trials

Registered studies

12 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 5
Recruiting: 4
Ph III recruiting: 0
Growth YoY: —
Industry share: 40%
Top sponsor: BridGene Biosciences Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07684287	A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma	not yet recruiting	Phase 2	40	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY	1	Jul 6, 2026	clinicaltrials

Data updated 22 days agoSource updated Jul 6, 2026source: clinicaltrials